PropertyValue
?:abstract
  • The sudden worldwide outbreak of Coronavirus Disease 2019 (COVID-19) has certainly provided new challenges in the management of acute ischaemic stroke, and the risk-benefit ratio of intravenous thrombolysis in COVID-19 positive patients is not well known. We describe four COVID-19 patients treated with intravenous thrombolysis for acute ischaemic stroke. Although rt-PA administration is the main therapeutic strategy, our patients experienced unpredictable complications and showed atypical features: the overall mortality was very high. In conclusion, in this article, we provide information about these cases and discuss the possible explanation behind this trend.
?:creator
?:doi
  • 10.1007/s10072-020-04591-3
?:doi
?:journal
  • Neurol_Sci
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/44e9687ba033dc0505d32b11d75bbfc9b17dd709.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7354364.xml.json
?:pmcid
?:pmid
?:pmid
  • 32656711.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • A single-centre experience of intravenous thrombolysis for stroke in COVID-19 patients
?:type
?:year
  • 2020-07-12

Metadata

Anon_0  
expand all